🏢 官网IRKURAQwen · 实盘不做把握 9/10不做原因:无增量信息🔁 +1 同一事件
北京时间·🕒 发布 09-04(美东日)仅日期·⟳ 抓取 09-05 19:16:32回填·⚡ 决策 09-13 21:57:37·43.7 天前
Kura Oncology 按 Nasdaq 规则 5635(c)(4) 向 4 名新员工授予 48,450 份行权价 $12.89 的诱导性期权，属例行人事激励公告，无交易含义
正文全文即一手公司新闻稿，内容为 Nasdaq 5635(c)(4) 下的例行新员工诱导性期权授予，无任何经营、临床、监管或资本层面的新增事实；Web/KB/行情均不可能改变“不做”的结论，故在首读阶段早停。
📄 原文KURA↗ 原文
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical…
不做 Kura Oncology（KURA.US）
例行 Nasdaq 5635(c)(4) 诱导性期权授予（4 名新员工、48,450 股、行权价 $12.89、四年归属），无临床/监管/订单/指引等任何经营增量事实，方向 NEUTRAL，无 edge；且当前为周末、美股闭市不可成交。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事实：KURA 于 2026-09-01 由薪酬委员会向 4 名新员工授予 48,450 份行权价 $12.89 的非法定期权，四年归属，依据 Nasdaq 5635(c)(4)，于 2026-09-04 通过 GlobeNewswire 发布。影响链：此类授予是招聘补偿的常规披露，不带来现金流变化、不改变管线价值或一致预期，期权规模相对已上市股本可忽略，且需在股价高于 $12.89 并持续任职后才有价值，因此既非利好也非实质利空。价格/证据：无金额、指引、临床或监管里程碑，事件本身不触发重定价。结论：方向 NEUTRAL，无可交易 edge，AVOID。
🔎 新鲜度:最早出现 2026-09-04 · 扩散 low · price-in 风险 low ↗
关键理由
- 无做多理由：授予为常规招聘激励，不含任何经营或管线增量信息，不构成股价催化
主要风险
- 唯一残余风险是该公告本身无信息量，若市场将其误读为稀释性事件可能带来极短期噪音波动，但规模太小不足以形成实质风险
先例如何影响了这次决策
对本次决策的影响:未影响决策，事件在事实层即已确定为非交易性
方向:未检索先例：例行诱导性期权授予属公认无价格信息含量的披露类型，历史反应统计不会改变“不做”的结论
涨幅量级:不适用，无幅度可校准
形态:不适用
原文全文
展开原文 · 2,187 字
SAN DIEGO
,
Sept. 04, 2026
(GLOBE NEWSWIRE) --
Kura Oncology, Inc.
(the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on
September 1, 2026
, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 48,450 shares of common stock to four (4) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to
$12.89
per share, the closing price of the Company’s common stock on
September 1, 2026
, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI
®
(ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory
NPM1
-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at
https://kuraoncology.com/
and follow us on
X
and
LinkedIn
.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
,
Sept. 04, 2026
(GLOBE NEWSWIRE) --
Kura Oncology, Inc.
(the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on
September 1, 2026
, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 48,450 shares of common stock to four (4) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to
$12.89
per share, the closing price of the Company’s common stock on
September 1, 2026
, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI
®
(ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory
NPM1
-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at
https://kuraoncology.com/
and follow us on
X
and
.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。